[Asia Economy Reporter Lee Gwanju] Shaperon announced on the 5th that it conducted a demand forecast targeting domestic and international institutional investors and finalized the public offering price at 5,000 KRW.
The demand forecast, held over two days from the 29th to 30th of last month, saw participation from 254 institutions, recording a competition rate of 25.94 to 1. The public offering amount is 13.7 billion KRW, and the market capitalization after listing is approximately 111.2 billion KRW.
Founded in 2008, Shaperon is developing anti-inflammatory therapeutics that treat inflammatory diseases such as atopic dermatitis, Alzheimer's dementia, idiopathic pulmonary fibrosis, and COVID-19, based on its proprietary inflammasome inhibition technology.
Last year, following the Alzheimer's dementia treatment technology transfer with Kukjeon Pharmaceuticals, this year in the first half, Shaperon completed a technology transfer (L/O) with Bridge Biotherapeutics for idiopathic pulmonary fibrosis, thereby enhancing the value of its pipeline.
Seong Seung-yong and Lee Myung-se, co-CEOs of Shaperon, stated, “With the funds secured through the IPO, we will prove Shaperon’s unique technological capabilities and growth potential, striving to ensure that the current public offering price is regarded by investors as a buying opportunity at a low price. After listing, based on excellent clinical results for each pipeline, we will share growth outcomes with investors through global technology transfers and expanding indications for the inflammasome inhibitor platform, becoming a new drug development company.”
Shaperon plans to list on KOSDAQ on the 17th of this month after subscription on the 6th and 7th. The lead underwriter is NH Investment & Securities.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
